Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19924578 | 0.79 | CHRM5 (0.32) | CHRM5ADRA2C | |
| SCHEMBL11199639 | 0.77 | CCR2 (0.36) | MAOBCYP2D6CHRM5ADRA2CCARM1 | |
| SCHEMBL4014571 | 0.75 | ADORA2A (0.33) | — | |
| SCHEMBL6992693 | 0.71 | ALDH1A1 (0.46) | — | |
| SCHEMBL2228489 | 0.71 | PTPN11 (0.32) | — | |
| SCHEMBL7547551 | 0.70 | KCNH2 (0.38) | CYP2D6CHRM5CARM1PRMT6 | |
| SCHEMBL3241046 | 0.69 | ALDH1A1 (0.44) | — | |
| SCHEMBL11199596 | 0.69 | CYP2D6 (0.60) | MAOBCYP2D6CARM1PRMT6 | |
| SCHEMBL3939637 | 0.68 | SIGMAR1 (0.41) | CHRM5 | |
| SCHEMBL8314496 | 0.67 | PRMT6 (0.31) | PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MCL1, TP53, TUBB3 | MAOB 1560/4885CYP2D6 1030/4885CHRM5 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.